Arexvy RSV Vaccine - Search News

Canada, RSV

GSK’s RSV vaccine approved in Canada for adults aged 50 to 59

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk for the disease.

CBC.ca · 4d

Canada approves Moderna's RSV vaccine for those age 60 and older, company says

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition.

Daily · 2d

GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused

Business Insider · 4d

Moderna receives Health Canada approval for RSV vaccine for 60 years, older

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease

The Canadian Press on MSN · 4d

Health Canada approves Moderna's mRNA RSV vaccine, company says

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older.

Medpage Today on MSN1d

Which High-Risk Patients Should Get the RSV Vaccine?

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Sierra Sun Times1d

UC San Francisco on New RSV Vaccine and Updated Vaccine Guidance for Seniors

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Business Wire20d

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk ...

Medpage Today on MSN1d

Real-World Data on the RSV Vaccine for Older Adults

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

BioPharma Dive13d

GSK vaccine sales sink on lower demand for RSV, shingles shots

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

4don MSN

Doctors stress the importance of the RSV vaccine

With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

14don MSN

GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

1don MSNOpinion

Opinion: The RSV vaccine will help protect older adults from the respiratory virus

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Canada approves GSK's RSV vaccine for adults aged 50 to 59

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results